| Bid Price | High Price | ||
|---|---|---|---|
| Ask Price | Low Price | ||
| Open Price | Spread | ||
| Prev Close | Volume |
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 23, 2018 | 4,971.00 | 5,028.00 | 4,971.00 | 5,015.00 | 1,571,971 |
| Apr 20, 2018 | 4,971.50 | 4,986.50 | 4,960.00 | 4,976.00 | 1,680,537 |
| Apr 19, 2018 | 4,976.00 | 5,015.00 | 4,937.50 | 4,955.50 | 1,839,174 |
| Apr 18, 2018 | 4,940.00 | 4,984.50 | 4,929.00 | 4,964.50 | 1,561,512 |
| Apr 17, 2018 | 4,925.50 | 4,935.00 | 4,875.00 | 4,927.00 | 2,052,990 |
| Company Name | AstraZeneca | Epic | AZN |
|---|---|---|---|
| ISIN | GB0009895292 | Currency | GBX |
| EMS | 500 | Prev Close | 5,015.00 |
| Shares in Issue (m) | 1,266.59 | Market Cap (£m) | 63,025.50 |
| PE Ratio | 21.00 | Div per Share (p) | 202.50 |
| Div Yield | 4.07 | Div Cover | 1.17 |
| EPS | 237.00 | EPS Growth (%) | -14.44 |
| PEG | -1.45 | DPS Growth (%) | -7.49 |
| ROCE | 4.74 | Net Gearing | 68.49 |
| Quick Ratio | 0.62 | Current Ratio | 0.80 |
| Date | Broker | Recomm. | Price | Old Target | New Target | Notes |
|---|---|---|---|---|---|---|
| 19 Apr | Shore Capital | Hold | 5,015.00 | - | 4,965.00 | Reiterates |
| 27 Mar | Morgan Stanley | Equal weight | 5,015.00 | 5,250.00 | 5,250.00 | Reiterates |
| 22 Mar | Exane BNP Paribas | Outperform | 5,015.00 | 5,600.00 | 5,600.00 | Reiterates |
| 20 Mar | Credit Suisse | Outperform | 5,015.00 | 5,800.00 | 5,800.00 | Reiterates |
| 19 Mar | Jefferies International | Buy | 5,015.00 | 5,075.00 | 5,600.00 | Upgrades |
| Date | Director | Type | Volume / Price | Trade Value |
|---|---|---|---|---|
| 28 Mar 2018 | Pascal Soriot | Transfer In | 11,998 @ 0.00p | £0.00 |
| 28 Mar 2018 | Marc Dunoyer | Transfer In | 3,768 @ 0.00p | £0.00 |
| 05 Feb 2018 | Philip Broadley | Buy | 415 @ 4,846.00p | £20,110.90 |
| 15 Dec 2017 | Pascal Soriot | Transfer Out | 39,648 @ 0.00p | £0.00 |
| 28 Jul 2017 | Philip Broadley | Buy | 2,300 @ 4,282.00p | £98,486.00 |
